D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 95 Citations 47,490 355 World Ranking 4809 National Ranking 2684

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Ribavirin
  • Virus

His main research concerns Internal medicine, Hepatitis C, Hepatitis C virus, Ribavirin and Immunology. The various areas that Mark S. Sulkowski examines in his Internal medicine study include Gastroenterology, Surgery, Viral load and Sofosbuvir. His Hepatitis C study integrates concerns from other disciplines, such as Hepatitis B, Interleukin 28B, Rapid Virologic Response, Coinfection and Cohort.

Mark S. Sulkowski combines subjects such as Liver disease and Hepatocellular carcinoma with his study of Hepatitis C virus. His work on Adverse effect expands to the thematically related Ribavirin. His Immunology research is multidisciplinary, relying on both Clinical trial and Ritonavir.

His most cited work include:

  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. (3072 citations)
  • Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (1943 citations)
  • Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection (1080 citations)

What are the main themes of his work throughout his whole career to date?

Mark S. Sulkowski mainly focuses on Internal medicine, Ribavirin, Gastroenterology, Hepatitis C and Hepatitis C virus. His studies deal with areas such as Chronic hepatitis, Surgery and Sofosbuvir as well as Internal medicine. His studies in Ribavirin integrate themes in fields like Interferon and Adverse effect.

His work in the fields of Gastroenterology, such as Cirrhosis, overlaps with other areas such as In patient. His Hepatitis C study results in a more complete grasp of Immunology. The concepts of his Hepatitis C virus study are interwoven with issues in Coinfection and Viral load.

He most often published in these fields:

  • Internal medicine (62.60%)
  • Ribavirin (40.24%)
  • Gastroenterology (39.43%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (62.60%)
  • Hepatitis C virus (36.99%)
  • Hepatitis C (37.20%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Internal medicine, Hepatitis C virus, Hepatitis C, Gastroenterology and Virology. His work deals with themes such as Coinfection and Ribavirin, Sofosbuvir, which intersect with Internal medicine. His Ribavirin research includes themes of Regimen, Adverse effect and NS5A.

His Hepatitis C virus research integrates issues from Direct acting, Viral load, Drug and Intensive care medicine. His research on Hepatitis C also deals with topics like

  • Care Continuum together with Public health,

  • Randomized controlled trial which intersects with area such as Nursing and Clinical trial. His Gastroenterology study also includes fields such as

  • Hepatitis B most often made with reference to Liver biopsy,

  • Ombitasvir, which have a strong connection to Ombitasvir/paritaprevir/ritonavir.

Between 2017 and 2021, his most popular works were:

  • Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial (149 citations)
  • The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study. (97 citations)
  • Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study (72 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Virus
  • Disease

His primary scientific interests are in Internal medicine, Gastroenterology, Hepatitis C virus, Hepatitis C and Sofosbuvir. Mark S. Sulkowski works mostly in the field of Internal medicine, limiting it down to topics relating to Paritaprevir and, in certain cases, Kidney disease. Mark S. Sulkowski has researched Gastroenterology in several fields, including Interquartile range, Liver biopsy, Regimen, Adverse effect and Ribavirin.

His Hepatitis C virus research is within the category of Virology. His research in Hepatitis C intersects with topics in Tailored treatment, Liver transplantation, Poisson regression, Hepatitis and Care Continuum. Mark S. Sulkowski interconnects Ledipasvir, Cirrhosis and Randomized controlled trial in the investigation of issues within Sofosbuvir.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Dongliang Ge;Jacques Fellay;Alexander J. Thompson;Jason S. Simon.
Nature (2009)

4267 Citations

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

Richard K. Sterling;Eduardo Lissen;Eduardo Lissen;Nathan Clumeck;Ricard Sola.
Hepatology (2006)

2503 Citations

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir.
The New England Journal of Medicine (2009)

1725 Citations

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

Nezam Afdhal;K. Rajender Reddy;David R. Nelson;Eric Lawitz.
The New England Journal of Medicine (2014)

1558 Citations

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

Mark S. Sulkowski;David F. Gardiner;Maribel Rodriguez-Torres;K. Rajender Reddy.
The New England Journal of Medicine (2014)

1475 Citations

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

John G. McHutchison;Gregory T. Everson;Stuart C. Gordon;Ira M. Jacobson.
The New England Journal of Medicine (2009)

1396 Citations

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida.
The New England Journal of Medicine (2013)

1343 Citations

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

Mark S. Sulkowski;David L. Thomas;Richard E. Chaisson;Richard D. Moore.
JAMA (2000)

1244 Citations

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Eric Lawitz;Mark S Sulkowski;Reem Ghalib;Maribel Rodriguez-Torres.
The Lancet (2014)

1046 Citations

Response-guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

Kenneth K.E. Sherman;Steven S.L. Flamm;Nezam N.H. Afdhal;David Nelson.
The New England Journal of Medicine (2011)

1027 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Mark S. Sulkowski

Stefan Zeuzem

Stefan Zeuzem

Goethe University Frankfurt

Publications: 204

Zobair M. Younossi

Zobair M. Younossi

Inova Health System

Publications: 176

Vincent Soriano

Vincent Soriano

Hospital Universitario La Paz

Publications: 165

Kazuaki Chayama

Kazuaki Chayama

Hiroshima University

Publications: 157

Gregory J. Dore

Gregory J. Dore

UNSW Sydney

Publications: 156

Raymond T. Chung

Raymond T. Chung

Harvard University

Publications: 132

Stanislas Pol

Stanislas Pol

Université Paris Cité

Publications: 131

Jean-Michel Pawlotsky

Jean-Michel Pawlotsky

Université Paris Cité

Publications: 119

Juan A. Pineda

Juan A. Pineda

Spanish National Research Council

Publications: 115

Heiner Wedemeyer

Heiner Wedemeyer

Hannover Medical School

Publications: 115

Hiromitsu Kumada

Hiromitsu Kumada

Fukuoka University

Publications: 107

Christoph Sarrazin

Christoph Sarrazin

Goethe University Frankfurt

Publications: 105

Ira M. Jacobson

Ira M. Jacobson

New York University

Publications: 105

Michael P. Manns

Michael P. Manns

Hannover Medical School

Publications: 98

Xavier Forns

Xavier Forns

University of Barcelona

Publications: 97

Pablo Barreiro

Pablo Barreiro

Hospital Universitario La Paz

Publications: 95

Something went wrong. Please try again later.